Selected Publications
Hughes WT, McDowell JA, Shenep J, Flynn P, Kline M, Yogev R, Symonds W, Lou Y, Heatherington S. Safety and single-dose pharmacokinetics of abacavir in human immunodeficiency virus type 1-infected children. Antimicrob Agents Chemother 43:609-15, 1999.
Ngo LY, Yogev R, Dankner WM, Hughes WT, Burchett S, Xu J, Sadler B, Unadakt JD. Pharmacokinetics of azithromycin administered alone and with atovaquone in HIV-infected children.Antimicrob Agents Chemother 43: 1516-9, 1999.
Oz HS, Hughes WT. DNA amplification from nasopharyngeal aspirates in rats: a procedure to detect Pneumocystis carinii. Microb Pathog 27:119-21, 1999.
Oz HS, Hughes WT, Rehg JE. Rat model for dual opportunistic pathogen prophylaxis: Cryptosporidium parvum and Pneumocystis carinii. Lab Anim Sci 49: 331-4, 1999.
Vargas S, Ponce C, Hughes WT, Wakefield A, Donosos S, Ulloa AV, Weitz JC, Madrid P, Gould S, Latorre JJ, Avila R, Benveniste S, Gallo M, Belleti J, Lopez R. Incidence of Pneumocystis carinii in lungs of 534 infants dying in the hospital compared to a group with sudden infant death syndrome (SIDS). Clin Infect Dis 29:1999.
Hughes WT, Dorenbaum A, Yogev R, Biauchamp B, Su J, McNamara J, Moye J, Purdue L, vanDyke R, Rogers M, Sadler B. A phase I safety and pharmacokinetics study of micronized atovaquone in human immunodeficiency virus - infected children. Antimicrob Agents Chemo 42: 1315-18, 1998.
Hughes WT. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infect Oncol 2: 1-7, 1998.
Hughes WT. Prologue to AIDS; The recognition of infectious opportunists. Medicine 77:227-232, 1998.
Englund JA, Baker CJ, Raskino C, McKinney RE, Petrie B, Fowler MG, Pearson D, Gershon A, McSherry GD, Abrams EJ, Schliozberg J, Sullivan JL, for the AIDS Clinical Trials Group (ACTG) Study 152 Team, [Shenep J, Hughes W, Flynn P, Slobod K]. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. N Engl J Med 336: 1704-12, 1997.
Hughes WT. Pneumocystis carinii pneumonitis. Infect Dis Clin Pract 6:379-84, 1997.
Hughes WT, Armstrong D, Bodey GP, Brown AE, Edwards JE, Feld R, Pizzo P, Rolston KVI, Shenep JL, Young LS. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 25:551-73, 1997.
Oz HS, Hughes WT. Novel anti-Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus, and dexamethasone. J Infect Dis 175:901-4, 1997.
Oz HS, Hughes WT. Pneumocystis carinii infection alters GTP-binding proteins in the lung. J Parasitol 83:679-85, 1997.
Oz HS, Hughes WT, Rehg JE. Efficacy of lasalocid against murine Pneumocystis carinii pneumonitis.Antimicrob Agents Chemother 41:191-2, 1997.
Pui C-H, Boyett JM, Hughes WT, Rivera GK, Hancock ML, Sandlund JT, Synold T, Relling MV, Ribeiro RC, Crist WM, Evans WE. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med 336:1781-7, 1997.
Hughes WT. Helicobacter pylori infection. Pediatr Ann 25:491-3, 1996.
Hughes WT. Opportunistic infections in children. H K J Paediatr 1:100-4, 1996.
Hughes WT. Pneumocystis cariniipneumonitis in patients with cancer. Infect Med 13:857,861-3,867, 1996.
Hughes WT. Recent advances in the prevention of Pneumocystis carinii pneumonia. Adv Pediatr Infect Dis 11:163-86, 1996.
Hughes WT, Killmar J. Monodrug efficacies of sulfonamides in prophylaxis for Pneumocystis carinii pneumonia. Antimicrob Agents Chemother 40:962-5, 1996.
Oz HS, Hughes WT. Acute fulminating babesiosis in hamsters infected with Babesia microti. Int J Parasitol 26:667-70, 1996.
Oz HS, Hughes WT. Effect of sex and dexamethasone dose on the experimental host for Pneumocystis carinii. Lab Anim Sci 46:109-10, 1996.
Oz HS, Hughes WT, Vargas SL. Search for extrapulmonary Pneumocystis carinii in an animal model.J Parasitol 82:357-9, 1996.
Last update: June 2012